Chandler Robinson - 31 Mar 2025 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role
Chief Executive Officer, Director
Signature
/s/ Quan Vu, Attorney-in-fact
Issuer symbol
MNPR
Transactions as of
31 Mar 2025
Net transactions value
-$43,838
Form type
4
Filing time
02 Apr 2025, 21:07:37 UTC
Previous filing
07 Mar 2025
Next filing
02 Jul 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MNPR Common Stock Options Exercise +4,106 +6.5% 67,197 31 Mar 2025 Direct F1
transaction MNPR Common Stock Tax liability $43,838 -1,204 -1.8% $36.41 65,993 31 Mar 2025 Direct F2
holding MNPR Common Stock 855,589 31 Mar 2025 See Footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MNPR Restricted Stock Units Options Exercise $0 -4,106 -4.2% $0.000000 94,669 31 Mar 2025 Common Stock 4,106 Direct F1, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired on vesting and settlement of restricted stock units.
F2 Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.
F3 As a manager of Tactic Pharma LLC, Dr. Robinson may be deemed to share voting and dispositive power over these 855,589 shares. Dr. Robinson disclaims beneficial ownership of the 855,589 shares held by Tactic Pharma LLC, except to the extent of his pecuniary interest therein.
F4 On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
F5 On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.